5-Amino-1MQ vs AOD-9604

Overview

5-Amino-1MQ and AOD-9604 are both researched for potential metabolic and fat loss effects, but they work through completely different mechanisms. 5-Amino-1MQ is a small molecule that inhibits the NNMT enzyme, while AOD-9604 is a modified fragment of human growth hormone. Neither is FDA-approved for weight loss, and both have significant evidence limitations.

This comparison helps researchers understand the different approaches to metabolic intervention and their respective evidence bases.

Key Facts

Aspect	5-Amino-1MQ	AOD-9604
Type	Small molecule	Peptide fragment
Structure	Methylquinolinium derivative	16 amino acids (GH fragment 176-191)
Target	NNMT enzyme	Fat cells (lipolysis)
Origin	Academic research	Metabolic Pharmaceuticals
FDA Status	Not approved	Not approved
TGA Status	Not approved	Approved (Australia, OTC)

Mechanism Comparison

Aspect	5-Amino-1MQ	AOD-9604
Primary Target	NNMT enzyme	Adipocyte receptors
Action	Enzyme inhibition	Lipolysis stimulation
Effect	Metabolic reprogramming	Fat breakdown
Systemic Scope	Broad metabolic	Fat-focused

5-Amino-1MQ Mechanism

1. NNMT Inhibition

   • Blocks nicotinamide N-methyltransferase
   • Preserves NAD+ precursors
   • Increases SAM availability
   • Metabolic pathway modulation

2. Metabolic Effects (Proposed)

   • Enhanced energy expenditure
   • White-to-beige fat conversion
   • Improved metabolic efficiency
   • NAD+ pathway optimization

3. Research Context

   • NNMT elevated in obesity
   • Mouse studies show metabolic benefits
   • Mechanism well-characterized

AOD-9604 Mechanism

1. Lipolytic Activity

   • Stimulates fat cell breakdown
   • Fragment of GH lipolytic region
   • Targets beta-3 adrenergic pathway
   • Mimics GH fat-burning effects

2. Selective Action (Claimed)

   • Fat loss without GH side effects
   • No IGF-1 increase
   • No blood glucose effects
   • Isolated lipolytic domain

3. Research Claims

   • Developed from GH research
   • Clinical trials conducted
   • Mixed results in humans

Evidence Quality

Factor	5-Amino-1MQ	AOD-9604
Human RCTs	None	Some (mixed results)
Animal Studies	Several	Several
Cell Studies	Yes	Yes
Mechanism Validation	Good	Moderate
Overall Evidence	Very Low	Low

5-Amino-1MQ Research

Study Type	Status	Findings
Mechanism studies	Good	NNMT inhibition confirmed
Mouse studies	Some	Metabolic improvements
Human trials	None	Not conducted
Cell studies	Yes	Adipocyte effects

AOD-9604 Research

Study Type	Status	Findings
Phase 2 trials	Completed	Did not meet primary endpoint
Phase 3 obesity	Failed	Discontinued
Cartilage repair	Ongoing	Different application
Regulatory	TGA approved	OTC in Australia

Clinical Trial History

5-Amino-1MQ

• No human clinical trials completed
• Preclinical research only
• Academic interest primarily
• No regulatory submissions

AOD-9604 Obesity Trials

Trial	Phase	Outcome
Early studies	1/2	Some promise
Phase 2b (obesity)	2b	Primary endpoint not met
Phase 3 (obesity)	3	Discontinued for lack of efficacy
Current focus	N/A	Shifted to cartilage repair

Regulatory Status

Aspect	5-Amino-1MQ	AOD-9604
FDA	Not approved	Not approved
TGA (Australia)	Not approved	Approved (OTC)
Classification	Research chemical	Listed medicine (AUS)
US Availability	Research chemical	Research chemical

AOD-9604 Australian Approval

• Approved by TGA for OTC sale
• Listed medicine (not evaluated for efficacy by TGA)
• Marketing claims restricted
• Not a statement of weight loss efficacy

Administration

Aspect	5-Amino-1MQ	AOD-9604
Route	Oral (research)	Subcutaneous injection
Oral Availability	Yes (proposed advantage)	Poor (requires injection)

Side Effect Profiles

5-Amino-1MQ

Concern	Status
Human safety data	None
NNMT role	May be needed for some functions
Long-term effects	Unknown
Drug interactions	Unknown

AOD-9604

Effect	Notes
Generally well-tolerated	In completed trials
Injection site reactions	Reported
Limited serious effects	In trial data
Long-term effects	Unknown

Comparison for Weight Loss Research

Factor	5-Amino-1MQ	AOD-9604
Mechanism Novelty	High (NNMT target)	Moderate (GH derivative)
Human Evidence	None	Exists but disappointing
Oral Option	Yes	No
Clinical History	None	Failed Phase 3

Why AOD-9604 Failed in Trials

Factor	Issue
Efficacy	Did not show significant weight loss vs placebo
Design	Adequate trial design
Mechanism	May not translate to meaningful effects
Comparison	GLP-1 drugs proved far more effective

Cost and Availability

Factor	5-Amino-1MQ	AOD-9604
Research Chemical	Available	Available
Relative Cost	Moderate	Moderate
Quality Variation	Significant	Significant
Verification	Possible	Possible

Comparison to Approved Drugs

vs Semaglutide (Wegovy)

Factor	5-Amino-1MQ	AOD-9604	Semaglutide
Evidence Level	Low	Low	Very High
Weight Loss	Unknown	~3% (trials)	15-17%
FDA Approval	No	No	Yes
Mechanism	NNMT	Lipolysis	GLP-1/appetite

Context

Both 5-Amino-1MQ and AOD-9604 have far less evidence than FDA-approved weight loss medications. The emergence of highly effective GLP-1 drugs has changed the obesity treatment landscape significantly.

Research Rationale

Why Study 5-Amino-1MQ?

Reason	Detail
Novel target	NNMT inhibition is new approach
Oral option	Potential for pill vs injection
Metabolic reprogramming	Beyond simple lipolysis
NAD+ connection	Ties to longevity research

Why Consider AOD-9604?

Reason	Detail
GH-derived	Theoretical selective benefit
Australian approval	Some regulatory acceptance
Safety profile	Appears well-tolerated
Combination potential	May add to other approaches

Summary

Factor	5-Amino-1MQ	AOD-9604
Type	Small molecule	Peptide
Mechanism	NNMT inhibition	Lipolysis
Human Trials	None	Yes (failed)
Evidence Level	Low	Low
Oral Option	Yes	No
Clinical History	None	Discontinued for obesity
Regulatory	Research chemical	TGA listed (AUS)

Key Takeaways

1. Different mechanisms: NNMT inhibition vs GH-like lipolysis
2. Neither proven in humans: 5-Amino-1MQ untested; AOD-9604 failed Phase 3
3. 5-Amino-1MQ is newer: Novel target without clinical validation
4. AOD-9604 has trial data: But trials were disappointing
5. Oral vs injectable: 5-Amino-1MQ potential oral; AOD-9604 requires injection
6. Both lag GLP-1 drugs: Approved drugs show far greater efficacy
7. Research interest differs: 5-Amino-1MQ ties to NAD+ biology; AOD-9604 to GH
8. Neither recommended: Both lack adequate human evidence for weight loss

---

This comparison is for educational purposes only. Neither compound is FDA-approved for weight loss. Both have limited evidence and should be considered experimental.